Clinical Guide: Intralobar Pulmonary Sequestration (ILS)

1. Comprehensive Introduction & Overview

Intralobar Pulmonary Sequestration (ILS) represents a rare congenital bronchopulmonary malformation characterized by a non-functioning segment of pulmonary parenchyma that lacks a normal connection to the tracheobronchial tree. Crucially, this sequestered tissue receives its blood supply from the systemic circulation, most commonly via an aberrant artery originating from the thoracic or abdominal aorta.

Unlike Extralobar Pulmonary Sequestration (ELS), which is enclosed within its own visceral pleura, ILS shares the visceral pleura of the adjacent normal lung. While historically categorized as a congenital anomaly, it is now widely recognized that many cases of ILS manifest as a result of recurrent localized pulmonary infection, leading some clinicians to view it as a hybrid of congenital and acquired pathology. It accounts for approximately 75% to 85% of all pulmonary sequestrations.

2. Deep-Dive: Etiology and Pathophysiology

The Embryological Basis

The prevailing theory for the development of ILS involves a "traction" mechanism. During early embryogenesis, an accessory lung bud arises from the foregut. If this bud migrates caudally with the developing lung, it may retain its systemic arterial supply. Because it is incorporated into the same pleura as the surrounding lung, it is termed "intralobar."

Pathophysiological Mechanisms

The hallmark of ILS is the systemic arterial supply. Because the sequestered tissue does not communicate with the tracheobronchial tree (or communicates poorly), it is prone to:
* Stasis of Secretions: Lack of mucociliary clearance leads to bacterial colonization.
* Recurrent Pneumonia: The sequestered segment often acts as a nidus for chronic infection.
* Vascular Shunting: The systemic arterial blood pressure entering the pulmonary circuit can lead to high-flow states and potential pulmonary hypertension if the sequestration is large.

Anatomical Distribution

3. Clinical Indications & Standard Presentation

Clinical Presentation

ILS is frequently asymptomatic in early life. Patients often present in late childhood or early adulthood following a history of recurrent respiratory infections.

1. Recurrent Pneumonia: The most frequent clinical indicator. Often located in the same anatomical site (usually the left lower lobe).
2. Chronic Cough: Productive of purulent sputum.
3. Hemoptysis: Occurs due to the high-pressure systemic arterial supply eroding into the bronchial tree.
4. Systemic Symptoms: Fever, malaise, and chest pain during acute infectious episodes.

Diagnostic Workup

Early diagnosis is critical to prevent bronchiectasis and permanent lung damage.

• Chest Radiography (CXR): Often shows a non-specific opacity, cystic lesion, or consolidation in the lower lobes.
• Computed Tomography (CT) Angiography: The gold standard. It allows for the visualization of the anomalous systemic artery feeding the sequestration.
• Magnetic Resonance Angiography (MRA): Used in patients where iodinated contrast is contraindicated.
• Bronchoscopy: Primarily used to rule out other causes of endobronchial obstruction, such as foreign bodies or tumors.

4. Risks, Side Effects, and Surgical Management

Risks of Untreated ILS

• Recurrent Infection: Leading to irreversible bronchiectasis.
• Massive Hemoptysis: Life-threatening erosion of the systemic artery.
• Abscess Formation: Development of chronic lung abscesses.
• High-Output Cardiac Failure: Rare, but possible with large sequestrations and high-flow shunts.

Surgical Intervention

Surgical resection (lobectomy or segmentectomy) is the definitive treatment for symptomatic ILS.

• Pre-operative Embolization: Increasingly used to occlude the systemic arterial supply, reducing the risk of intraoperative hemorrhage.
• VATS (Video-Assisted Thoracoscopic Surgery): The current preferred surgical approach, offering faster recovery times and reduced morbidity compared to open thoracotomy.

Contraindications

• Asymptomatic patients: There is ongoing debate regarding prophylactic resection in asymptomatic patients. However, most experts recommend surgery to prevent future infectious complications.
• Severe comorbidities: In patients who are poor surgical candidates, conservative management with aggressive antibiotic therapy and monitoring may be necessary.

5. Differential Diagnosis

Distinguishing ILS from other thoracic pathologies is essential for surgical planning:

1. Congenital Pulmonary Airway Malformation (CPAM): Often involves cystic communication with the airway.
2. Bronchogenic Cyst: Usually mediastinal, but can be intrapulmonary.
3. Pulmonary Abscess: Typically lacks the systemic arterial supply characteristic of ILS.
4. Infected Bullae/Pneumatocele: Lacks the vascular component of sequestration.
5. Neoplasia: Bronchial carcinoids or other tumors must be ruled out in adult patients presenting with hemoptysis.

6. Massive FAQ Section

1. Is Intralobar Pulmonary Sequestration hereditary?
No, it is considered a sporadic developmental anomaly and is not linked to specific hereditary genetic patterns.

2. Can ILS be diagnosed during pregnancy?
Yes, high-resolution fetal ultrasound can sometimes identify a hyperechoic mass in the fetal chest, prompting closer monitoring.

3. Why is it called "Intralobar"?
It is called "intralobar" because the sequestered tissue is contained within the same pleural envelope as the normal lobe of the lung, making dissection slightly more complex than the "extralobar" type.

4. What is the most common location for ILS?
The left lower lobe is the most frequent site, accounting for approximately 60% of all cases, followed by the right lower lobe.

5. Does ILS always require surgery?
While asymptomatic cases are sometimes monitored, the consensus is that surgical resection is the treatment of choice to prevent chronic infection and life-threatening bleeding.

6. What happens if the systemic artery is missed during surgery?
Missing the systemic arterial supply during surgery can lead to catastrophic intraoperative hemorrhage. This is why preoperative CT angiography is non-negotiable.

7. Can ILS cause heart problems?
In rare cases of large sequestrations, the systemic-to-pulmonary shunt can lead to an increased workload on the left ventricle, potentially resulting in high-output cardiac failure.

8. What is the prognosis after surgery?
The prognosis is excellent. Once the sequestered segment is removed, patients typically experience complete resolution of symptoms and no further pulmonary infections.

9. Is there a difference between ILS and a lung abscess?
Yes. While ILS often becomes an abscess, the underlying etiology is the anomalous blood supply, which is not present in a standard primary lung abscess.

10. Can ILS recur after surgery?
True recurrence after complete surgical excision is extremely rare. If symptoms persist, it usually suggests that a portion of the sequestered tissue was left behind.

7. Long-Term Prognosis and Clinical Outlook

The long-term outlook for patients diagnosed with ILS is highly favorable, provided that the diagnosis is made before extensive bronchiectasis develops in the surrounding lung tissue. Post-surgical follow-up usually involves a single imaging review (CXR or CT) to confirm the integrity of the remaining parenchyma.

Key Takeaways for Clinicians

• Maintain a high index of suspicion: Any patient with recurrent lower lobe infections should undergo CT angiography to rule out systemic arterial supply.
• Prioritize vascular mapping: Never attempt surgery without clear identification of the systemic feeder vessel.
• Advocate for early intervention: Proactive resection in stable patients prevents the "vicious cycle" of inflammation and tissue destruction.

Summary Table: Diagnostic Summary

This guide serves as a foundational resource for clinical management. Given the rarity of ILS, consultation with a multidisciplinary team—including thoracic surgeons, interventional radiologists, and pulmonologists—is recommended for every case.